Sionna Therapeutics, Inc.

NASDAQ:SION

Biotechnology

Healthcare
$2.97 +1.85%

+$0.68 today

Market cap
$134.35M
Beta
1.29
P/E (TTM)
-19.7
EPS (TTM)
-$1.90
52W Low $13.81High $48.45

Volume 0.52M

Average 0.39M

SION Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Sionna Therapeutics, Inc.NASDAQ: SION

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$283.13M, compared with -$197.57M a year earlier.

Context

  • Retained earnings amounted to 92.8% of total assets at the end of Q1 FY2026, up 39.4 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -43.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$283.13M-10.4% QoQ
Last fiscal yearDec 2025
-$256.35M-41.6% YoY
Year agoMar 2025
-$197.57M-43.3% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-43.3%——
1 year-41.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(256.35M) USD
Year-over-year change
-41.6%

Retained Earnings vs competitors

How SION compares with its peers on the latest reported figures

  • SION's Mar 2026 retained earnings of -$283.13M is the 2nd highest of the 11 companies compared; the peer median is -$962.73M.
  • Its year-over-year change of -43.3% is the 8th highest of 11, against a peer median of -32.3%.
  • Retained earnings amounts to 92.8% of total assets for SION, versus a peer median of 178.3%.
SION Competitors Peer median
Retained Earnings for SION and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABCLAbCellera Biologics Inc.Sep 2026-$168.83M -722.1%—11.3%
SIONSionna Therapeutics, Inc.Mar 2026-$283.13M -43.3%—92.8%
JANXJanux Therapeutics, Inc.Mar 2026-$375.74M -43.8%—36.5%
MAZEMaze Therapeutics, Inc.Mar 2026-$513.76M -31.3%—122.4%
XERSXeris Biopharma Holdings, Inc.Mar 2026-$669.07M +1.8%—170.7%
IMNMImmunome, Inc.Sep 2026-$940.91M -42.9%—186.1%
ARDXArdelyx, Inc.Mar 2026-$984.54M -6.3%—195.1%
VERAVera Therapeutics, Inc.Jun 2026-$991.37M -68.2%—186.0%
ZYMEZymeworks Inc.Sep 2026-$1.01B -13.9%—85.8%
CLDXCelldex Therapeutics, Inc.Sep 2026-$2.04B -17.8%—283.0%
BHVNBiohaven Ltd.Jun 2026-$2.35B -33.2%—634.5%
Peer median (excluding SION) -$962.73M-32.3%—178.3%

Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents54.84M38.52M37.79M58.45M
Short-term Investments27.77M0109.75M177.43M
Net Receivables0000
Inventory0000
Other Current Assets1.22M686K3.46M5.54M
Total Current Assets83.83M39.21M150.99M241.42M
Property, Plant & Equipment (Net)2.57M11.73M10.3M9.15M
Goodwill0000
Intangible Assets0000
Long-term Investments0962K20.51M74.42M
Tax Assets0000
Other Non-current Assets962K44K3.96M963K
Total Non-current Assets3.54M12.74M34.76M84.53M
Total Assets87.37M51.95M185.75M325.95M
Account Payables557K719K1.19M769K
Short-term Debt0000
Tax Payables0000
Deferred Revenue0000
Other Current Liabilities1.95M3.11M2.97M4.75M
Total Current Liabilities8.25M8.04M10.42M11.71M
Long-term Debt0000
Deferred Tax Liabilities0000
Deferred Revenue (Non-current)0000
Other Non-current Liabilities149.04M149.04M330.37M0
Total Non-current Liabilities149.04M158.79M339.05M7.41M
Total Liabilities157.29M166.83M349.47M19.12M
Common Stock2K2K5K45K
Retained Earnings(72.14M)(119.4M)(181.09M)(256.35M)
Accumulated OCI(16K)0368K540K
Other Stockholders Equity(149.04M)(149.04M)(330.37M)0
Minority Interest0000
Total Equity(69.92M)(114.88M)(163.71M)306.83M
Total Debt010.48M9.75M8.68M
Net Debt(54.84M)(28.04M)(28.04M)(49.77M)

Sionna Therapeutics, Inc.

NASDAQ:SION

Intrinsic Alpha fair value

Locked

Current Price

$2.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.